Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
Sofinnova Investments, Inc.
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$2.6B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
75
positionsALL retained default holdings for this (filer, period), including NULL-value ones
30
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
16
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
iShares TR RUSSELL 2000 ETFposition key pos:16595 · issuer key iss:1231 PUT | new | +$149M | +600,000 | $0 | $149M | — | 600,000 | |
SPDR Series Trust STATE STREET SPDposition key pos:10981 · issuer key iss:1900 PUT | new | +$134M | +1,050,000 | $0 | $134M | — | 1,050,000 | |
Bristol-Myers Squibb Co COMposition key pos:15894 · issuer key iss:435 | add | +$39.0M | +475,727 | $81.6M | $121M | 1,512,994 | 1,988,721 | |
Jazz Pharmaceuticals PLC SHS USDposition key pos:15540 · issuer key iss:2545 | trim | −$50.1M | −361,533 | $163M | $113M | 959,860 | 598,327 | |
United Therapeutics Corp COMposition key pos:15902 · issuer key iss:2217 | add | +$18.1M | +2,429 | $76.8M | $94.9M | 157,641 | 160,070 | |
AstraZeneca PLC ORDposition key pos:18610 · issuer key iss:2433 | new | +$89.9M | +456,031 | $0 | $89.9M | — | 456,031 | |
Invesco QQQ TR UNIT SER 1position key pos:12022 · issuer key iss:1207 PUT | new | +$86.6M | +150,000 | $0 | $86.6M | — | 150,000 | |
Cogent Biosciences Inc COMposition key pos:18333 · issuer key iss:610 | add | +$11.2M | +139,926 | $70.1M | $81.4M | 1,973,625 | 2,113,551 | |
iShares TR ISHARES BIOTECHposition key pos:14750 · issuer key iss:1231 PUT | new | +$80.2M | +475,000 | $0 | $80.2M | — | 475,000 | |
Ultragenyx Pharmaceutical Inc COMposition key pos:16570 · issuer key iss:2194 | add | +$64.0M | +3,062,588 | $1.9M | $65.9M | 83,300 | 3,145,888 | |
Insmed Inc COM PAR $.01position key pos:15087 · issuer key iss:1181 | add | +$29.3M | +189,274 | $27.3M | $56.6M | 156,801 | 346,075 | |
Alcon AG ORD SHSposition key pos:18699 · issuer key iss:2659 | add | +$28.8M | +397,452 | $26.2M | $55.0M | 332,520 | 729,972 | |
Supernus Pharmaceuticals COMposition key sid:sec:prov:38b7ce53f517b4f397d48b58dc3386d9 · issuer key cusip6:868459 | add | +$21.8M | +401,214 | $27.5M | $49.3M | 553,095 | 954,309 | |
United Therapeutics Corp COMposition key pos:15902 · issuer key iss:2217 PUT | new | +$47.6M | +80,300 | $0 | $47.6M | — | 80,300 | |
BioMarin Pharmaceutical Inc COMposition key pos:11882 · issuer key iss:375 | add | +$2.7M | +84,849 | $41.4M | $44.2M | 697,133 | 781,982 | |
Biogen Inc COMposition key pos:12302 · issuer key iss:376 | new | +$42.1M | +229,521 | $0 | $42.1M | — | 229,521 | |
Celcuity Inc COMposition key pos:11232 · issuer key iss:542 | add | +$11.9M | +66,758 | $29.9M | $41.8M | 299,417 | 366,175 | |
Rhythm Pharmaceuticals Inc COMposition key pos:17607 · issuer key iss:1846 | add | +$10.1M | +178,702 | $29.1M | $39.1M | 271,394 | 450,096 | |
IDEAYA Biosciences Inc COMposition key sid:sec:prov:f7d48a640772d3aa60939ca4949078c5 · issuer key cusip6:45166A | add | +$7.1M | +246,665 | $30.6M | $37.7M | 885,121 | 1,131,786 | |
Immunome Inc COMposition key pos:15236 · issuer key iss:1165 | add | +$2.5M | +83,427 | $34.8M | $37.2M | 1,618,477 | 1,701,904 | |
Nektar Therapeutics COMposition key sid:sec:prov:8689270ade82a464b05b5b23e79f9006 · issuer key cusip6:640268 | add | +$18.1M | +70,916 | $18.5M | $36.7M | 438,630 | 509,546 | |
Axsome Therapeutics Inc. COMposition key pos:13938 · issuer key iss:295 | add | +$33.7M | +200,481 | $2.2M | $36.0M | 12,266 | 212,747 | |
Immatics N.V SHSposition key sid:sec:prov:8771e17f16590b5bd511978f2a4f7807 · issuer key cusip6:N44445 | add | −$350K | +194,912 | $36.1M | $35.7M | 3,435,542 | 3,630,454 | |
Celcuity Inc COMposition key pos:11232 · issuer key iss:542 PUT | new | +$34.2M | +300,000 | $0 | $34.2M | — | 300,000 | |
Axsome Therapeutics Inc. COMposition key pos:13938 · issuer key iss:295 PUT | new | +$33.8M | +200,000 | $0 | $33.8M | — | 200,000 | |
BridgeBio Pharma Inc COMposition key pos:15468 · issuer key iss:427 | trim | −$24.7M | −311,265 | $55.1M | $30.4M | 720,448 | 409,183 | |
Dyne Therapeutics Inc COMposition key pos:14578 · issuer key iss:778 | trim | −$14.5M | −620,264 | $44.1M | $29.6M | 2,254,161 | 1,633,897 | |
Inhibrx Biosciences Inc COMposition key pos:16847 · issuer key iss:1178 | trim | −$8.6M | −48,628 | $35.9M | $27.3M | 454,657 | 406,029 | |
Dexcom Inc COMposition key pos:15920 · issuer key iss:727 | add | −$386K | +15,357 | $25.1M | $24.7M | 378,219 | 393,576 | |
Pharvaris N V COMposition key pos:15462 · issuer key iss:2706 | add | +$2.4M | +73,159 | $20.7M | $23.1M | 745,169 | 818,328 | |
Pfizer Inc COMposition key pos:11636 · issuer key iss:1709 CALL | new | +$22.5M | +800,000 | $0 | $22.5M | — | 800,000 | |
Praxis Precision Medicines Inc COMposition key pos:11991 · issuer key iss:1748 | trim | −$16.5M | −62,042 | $37.1M | $20.5M | 125,722 | 63,680 | |
Genmab A/S SPONSORED ADSposition key pos:17380 · issuer key iss:1001 | new | +$20.2M | +752,261 | $0 | $20.2M | — | 752,261 | |
Arcus Biosciences Inc COMposition key sid:sec:prov:3c51cfeec4a5be695bdb08ebfaa41e00 · issuer key cusip6:03969F | trim | −$6.2M | −173,619 | $26.1M | $19.9M | 1,096,705 | 923,086 | |
Liquidia Corporation COMposition key pos:15663 · issuer key iss:1361 PUT | new | +$18.9M | +500,000 | $0 | $18.9M | — | 500,000 | |
Xenon Pharmaceuticals Inc COMposition key pos:13384 · issuer key iss:2365 | add | +$15.1M | +245,316 | $2.7M | $17.7M | 59,900 | 305,216 | |
Stryker Corporation COMposition key pos:16108 · issuer key iss:2049 | new | +$14.6M | +44,480 | $0 | $14.6M | — | 44,480 | |
AnaptysBio Inc COMposition key pos:18179 · issuer key iss:200 | trim | −$179K | −39,437 | $13.9M | $13.8M | 287,690 | 248,253 | |
Roivant Sciences Ltd SHSposition key pos:18572 · issuer key iss:2604 | trim | −$2.7M | −256,587 | $15.9M | $13.2M | 734,582 | 477,995 | |
Edgewise Therapeutics Inc COMposition key pos:12663 · issuer key iss:796 | trim | +$1.3M | −51,321 | $10.9M | $12.2M | 437,819 | 386,498 | |
Compass Therapeutics Inc COMposition key sid:sec:prov:c5f3f37de4d48fd1b29c266e9a76eb0b · issuer key cusip6:20454B | trim | −$7.2M | −1,309,285 | $18.1M | $10.9M | 3,365,446 | 2,056,161 | |
Exelixis Inc COMposition key pos:15702 · issuer key iss:870 PUT | new | +$10.8M | +251,500 | $0 | $10.8M | — | 251,500 | |
Oric Pharmaceuticals Inc COMposition key pos:11546 · issuer key iss:1634 | new | +$8.6M | +679,578 | $0 | $8.6M | — | 679,578 | |
Tango Therapeutics Inc COMposition key pos:12388 · issuer key iss:2086 | new | +$8.3M | +395,081 | $0 | $8.3M | — | 395,081 | |
Tyra Biosciences Inc COMposition key sid:sec:prov:47170149b82e95e4444c881acffa67fc · issuer key cusip6:90240B | new | +$7.8M | +204,015 | $0 | $7.8M | — | 204,015 | |
Replimune Group Inc COMposition key pos:13385 · issuer key iss:1836 CALL | new | +$7.8M | +1,015,400 | $0 | $7.8M | — | 1,015,400 | |
Ultragenyx Pharmaceutical Inc COMposition key pos:16570 · issuer key iss:2194 CALL | new | +$7.3M | +350,000 | $0 | $7.3M | — | 350,000 | |
AxoGen Inc COMposition key sid:sec:prov:fd61a14f8c16900d70648b14bc187bfb · issuer key cusip6:05463X | new | +$7.0M | +210,665 | $0 | $7.0M | — | 210,665 | |
Definium Therapeutics Inc COM SHSposition key pos:17580 · issuer key iss:717 | new | +$6.5M | +344,166 | $0 | $6.5M | — | 344,166 | |
Cytokinetics Inc COMposition key pos:13331 · issuer key iss:700 | new | +$6.0M | +91,791 | $0 | $6.0M | — | 91,791 | |
Disc Medicine Inc COMposition key pos:13022 · issuer key iss:741 | trim | −$3.8M | −32,690 | $8.8M | $5.0M | 111,010 | 78,320 | |
Veradermics Inc COMMON STOCKposition key pos:15115 · issuer key iss:2252 | new | +$4.6M | +73,315 | $0 | $4.6M | — | 73,315 | |
Harmony Biosciences Hldgs Inc COMposition key pos:14335 · issuer key iss:1083 | new | +$4.3M | +152,695 | $0 | $4.3M | — | 152,695 | |
Vaxcyte Inc COMposition key pos:12513 · issuer key iss:2248 | new | +$2.9M | +50,600 | $0 | $2.9M | — | 50,600 | |
Compass Therapeutics Inc COMposition key sid:sec:prov:c5f3f37de4d48fd1b29c266e9a76eb0b · issuer key cusip6:20454B CALL | new | +$2.6M | +500,000 | $0 | $2.6M | — | 500,000 | |
Mirum Pharmaceuticals Inc COMposition key pos:12357 · issuer key iss:1485 | add | +$724K | +4,491 | $1.8M | $2.5M | 23,100 | 27,591 | |
Savara Inc COMposition key sid:sec:prov:2bc6a25d40cf07124e3a03bdecf4a4df · issuer key cusip6:805111 | add | +$154K | +59,993 | $1.8M | $2.0M | 304,770 | 364,763 | |
Establishment Labs Hldgs Inc COMposition key sid:sec:prov:7bf59fd7aeffb1ecf2ffdacd97c7e39d · issuer key cusip6:G31249 | add | −$141K | +5,564 | $2.1M | $1.9M | 28,366 | 33,930 | |
Acadia Pharmaceuticals Inc COMposition key pos:18889 · issuer key iss:56 | add | −$2.8K | +12,984 | $1.8M | $1.7M | 65,567 | 78,551 | |
Tenax Therapeutics Inc COMposition key sid:sec:prov:9e958f4e10d0d474cc9e75d42ea33a9a · issuer key cusip6:88032L | new | +$1.7M | +104,400 | $0 | $1.7M | — | 104,400 | |
Wave Life Sciences Ltd SHSposition key pos:15162 · issuer key iss:2734 | add | −$1.3M | +31,071 | $2.7M | $1.4M | 158,182 | 189,253 | |
Septerna Inc COMposition key sid:sec:prov:c07b19289bd1953ef889bf232426771d · issuer key cusip6:81734D | new | +$1.1M | +47,506 | $0 | $1.1M | — | 47,506 | |
Onkure Therapeutics Inc COM CL Aposition key sid:sec:prov:1b29f8f31311ff2217960a31a2f84a8d · issuer key cusip6:68277Q | new | +$587K | +141,700 | $0 | $587K | — | 141,700 | |
Soleno Therapeutics Inc COMposition key sid:sec:prov:9c654c0b85e21e330a7ebfd2ced217c7 · issuer key cusip6:834203 | add | −$83.0K | +2,275 | $575K | $492K | 12,414 | 14,689 | |
Zymeworks Inc COMposition key sid:sec:prov:cc436d9af4067ff4382c62284d4ff9e5 · issuer key cusip6:98985Y | new | +$40.3K | +1,610 | $0 | $40.3K | — | 1,610 | |
| pos:11430 | exit‡e | −$74.6M | −164,594 | $74.6M | $0 | 164,594 | — | |
| pos:11923 | exit‡e | −$4.2M | −176,513 | $4.2M | $0 | 176,513 | — | |
| pos:14112 | exit‡e | −$40.4M | −534,845 | $40.4M | $0 | 534,845 | — | |
| pos:16392 | exit‡e | −$72.6M | −317,783 | $72.6M | $0 | 317,783 | — | |
| pos:16702 | exit‡e | −$32.5M | −288,128 | $32.5M | $0 | 288,128 | — | |
| pos:16757 | exit‡e | −$66.3M | −61,652 | $66.3M | $0 | 61,652 | — | |
| pos:17257 | exit‡e | −$13.2M | −160,876 | $13.2M | $0 | 160,876 | — | |
| pos:17712 | exit‡e | −$71.9M | −126,968 | $71.9M | $0 | 126,968 | — | |
| pos:18367 | exit‡e | −$150M | −1,632,334 | $150M | $0 | 1,632,334 | — | |
| pos:18882 | exit‡e | −$27.6M | −1,104,274 | $27.6M | $0 | 1,104,274 | — | |
| sid:sec:prov:003ec1a792a63a6ca1608977e0029001 | exit‡e | −$6.0M | −46,201 | $6.0M | $0 | 46,201 | — | |
| sid:sec:prov:636025167f135725718ab65e5347aeb8 | exit‡e | −$10.3M | −101,443 | $10.3M | $0 | 101,443 | — | |
| sid:sec:prov:6456a8a739b1b376bb8de72f440b1279 | exit‡e | −$6.4M | −527,099 | $6.4M | $0 | 527,099 | — | |
| sid:sec:prov:adbff6ad799c41f5a1fe4cddc6ffc42b | exit‡e | −$2.6M | −153,320 | $2.6M | $0 | 153,320 | — | |
| sid:sec:prov:b436d0646c9759c2ba692c8fcd7924ab | exit‡e | −$39.8M | −180,265 | $39.8M | $0 | 180,265 | — | |
| sid:sec:prov:fc7c842ed91a7e3b374f2a94cbad8d9a | exit‡e | −$53.7M | −745,116 | $53.7M | $0 | 745,116 | — |
61 more changes below.
Mark-to-market only (no share change) · 9
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
Natera Inc COMposition key pos:14059 · issuer key iss:1529 | no change | −$45.1M | 0 | $355M | $310M | 1,550,280 | 1,550,280 | |
Vera Therapeutics Inc CL Aposition key sid:sec:prov:c6f0567aff349dfe2dab4a6ee5ba8988 · issuer key cusip6:92337R | no change | −$29.1M | 0 | $141M | $112M | 2,793,987 | 2,793,987 | |
Rapport Therapeutics Inc COMposition key sid:sec:prov:9fd554b76cc510ac236cd887d1f06195 · issuer key cusip6:75383L | no change | +$1.8M | 0 | $57.8M | $59.6M | 1,904,408 | 1,904,408 | |
BioAge Labs Inc COMposition key sid:sec:prov:09a6575686667c84597e4fe2b4841977 · issuer key cusip6:09077V | no change | +$9.8M | 0 | $30.3M | $40.1M | 2,293,788 | 2,293,788 | |
Arrivent BioPharma Inc COMposition key sid:sec:prov:1a78f2f31f5e82c1522796ab4aa69fd1 · issuer key cusip6:04272N | no change | +$5.0M | 0 | $34.1M | $39.1M | 1,696,752 | 1,696,752 | |
Nextcure Inc COMposition key sid:sec:prov:60b0d2b7a0a89427b98ad9e1fd59d494 · issuer key cusip6:65343E | no change | −$782K | 0 | $3.2M | $2.4M | 222,654 | 222,654 | |
Jade Biosciences Inc COMposition key sid:sec:prov:3b4a08cf659449a1ac1d2ee41e501b50 · issuer key cusip6:008064 | no change | −$148K | 0 | $1.7M | $1.5M | 107,391 | 107,391 | |
Bolt Biotherapeutics Inc COMposition key sid:sec:prov:4e1251cac1f489d2ab1b0a155436af89 · issuer key cusip6:097702 | no change | −$197K | 0 | $753K | $556K | 137,721 | 137,721 | |
ImageneBio Inc COMposition key sid:sec:prov:6db6b47119928ad4af3cf49015c9c5eb · issuer key cusip6:45175G | no change | −$60.6K | 0 | $220K | $159K | 31,884 | 31,884 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 77.0%below median 80.0%
- Concentration index
- 374 bpsbelow median 446 bps
- Positions with value
- 75 / 75median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 77.0% · HHI (bps) ·§: 374integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 90
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open Sofinnova Investments, Inc.'s 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–68 of 68 issuers · $2.6B disclosed value over 75 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | NTRAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Natera Inc Natera Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $310M | 1,550,280 | — | 11.8% | — | |
| — | — | iShares TR | $229M | 1,075,000 | — | 8.7% | — | |
| — | UTHRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | United Therapeutics Corp | $143M | 240,370 | — | 5.4% | — | |
| — | — | SPDR Series Trust SPDR Series Trust · STATE STREET SPD · PUT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $134M | 1,050,000 | — | 5.1% | — | |
| — | BMYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Bristol-Myers Squibb Co Bristol-Myers Squibb Co · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $121M | 1,988,721 | — | 4.6% | — | |
| — | JAZZverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC · SHS USD CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $113M | 598,327 | — | 4.3% | — | |
| — | — | Vera Therapeutics Inc Vera Therapeutics Inc · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $112M | 2,793,987 | — | 4.3% | — | |
| — | AZNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AstraZeneca PLC AstraZeneca PLC · ORD CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $89.9M | 456,031 | — | 3.4% | — | |
| — | QQQverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Invesco QQQ TR Invesco QQQ TR · UNIT SER 1 · PUT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $86.6M | 150,000 | — | 3.3% | — | |
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Cogent Biosciences Inc Cogent Biosciences Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $81.4M | 2,113,551 | — | 3.1% | — | |
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Celcuity Inc | $76.0M | 666,175 | — | 2.9% | — | |
| — | — | Ultragenyx Pharmaceutical Inc | $73.2M | 3,495,888 | — | 2.8% | — | |
| — | AXSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Axsome Therapeutics Inc. | $69.8M | 412,747 | — | 2.7% | — | |
| — | — | Rapport Therapeutics Inc Rapport Therapeutics Inc · COM CUSIP 75383L102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $59.6M | 1,904,408 | — | 2.3% | — | |
| — | INSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Insmed Inc Insmed Inc · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $56.6M | 346,075 | — | 2.2% | — | |
| — | ALCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Alcon AG Alcon AG · ORD SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $55.0M | 729,972 | — | 2.1% | — | |
| — | — | Supernus Pharmaceuticals Supernus Pharmaceuticals · COM CUSIP 868459108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $49.3M | 954,309 | — | 1.9% | — | |
| — | BMRNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BioMarin Pharmaceutical Inc BioMarin Pharmaceutical Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $44.2M | 781,982 | — | 1.7% | — | |
| — | BIIBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Biogen Inc Biogen Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $42.1M | 229,521 | — | 1.6% | — | |
| — | — | BioAge Labs Inc BioAge Labs Inc · COM CUSIP 09077V100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $40.1M | 2,293,788 | — | 1.5% | — | |
| — | RYTMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $39.1M | 450,096 | — | 1.5% | — | |
| — | — | Arrivent BioPharma Inc Arrivent BioPharma Inc · COM CUSIP 04272N102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $39.1M | 1,696,752 | — | 1.5% | — | |
| — | — | IDEAYA Biosciences Inc IDEAYA Biosciences Inc · COM CUSIP 45166A102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $37.7M | 1,131,786 | — | 1.4% | — | |
| — | IMNMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Immunome Inc Immunome Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $37.2M | 1,701,904 | — | 1.4% | — | |
| — | — | Nektar Therapeutics Nektar Therapeutics · COM CUSIP 640268306 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $36.7M | 509,546 | — | 1.4% | — | |
| — | — | Immatics N.V Immatics N.V · SHS CUSIP N44445109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.7M | 3,630,454 | — | 1.4% | — | |
| — | BBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BridgeBio Pharma Inc BridgeBio Pharma Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $30.4M | 409,183 | — | 1.2% | — | |
| — | DYNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Dyne Therapeutics Inc Dyne Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $29.6M | 1,633,897 | — | 1.1% | — | |
| — | INBXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Inhibrx Biosciences Inc Inhibrx Biosciences Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.3M | 406,029 | — | 1.0% | — | |
| — | DXCMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Dexcom Inc Dexcom Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.7M | 393,576 | — | 0.9% | — | |
| — | PHVSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Pharvaris N V Pharvaris N V · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $23.1M | 818,328 | — | 0.9% | — | |
| — | PFEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Pfizer Inc Pfizer Inc · COM · CALL CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.5M | 800,000 | — | 0.9% | — | |
| — | — | Praxis Precision Medicines Inc Praxis Precision Medicines Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.5M | 63,680 | — | 0.8% | — | |
| — | GMABverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Genmab A/S Genmab A/S · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.2M | 752,261 | — | 0.8% | — | |
| — | — | Arcus Biosciences Inc Arcus Biosciences Inc · COM CUSIP 03969F109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.9M | 923,086 | — | 0.8% | — | |
| — | — | Liquidia Corporation Liquidia Corporation · COM · PUT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.9M | 500,000 | — | 0.7% | — | |
| — | XENEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.7M | 305,216 | — | 0.7% | — | |
| — | SYKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Stryker Corporation Stryker Corporation · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.6M | 44,480 | — | 0.6% | — | |
| — | ANABverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AnaptysBio Inc AnaptysBio Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.8M | 248,253 | — | 0.5% | — | |
| — | — | Compass Therapeutics Inc | $13.5M | 2,556,161 | — | 0.5% | — | |
| — | ROIVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Roivant Sciences Ltd Roivant Sciences Ltd · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.2M | 477,995 | — | 0.5% | — | |
| — | EWTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Edgewise Therapeutics Inc Edgewise Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.2M | 386,498 | — | 0.5% | — | |
| — | EXELverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Exelixis Inc Exelixis Inc · COM · PUT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.8M | 251,500 | — | 0.4% | — | |
| — | ORICverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Oric Pharmaceuticals Inc Oric Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.6M | 679,578 | — | 0.3% | — | |
| — | TNGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Tango Therapeutics Inc Tango Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.3M | 395,081 | — | 0.3% | — | |
| — | — | Tyra Biosciences Inc Tyra Biosciences Inc · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.8M | 204,015 | — | 0.3% | — | |
| — | REPLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Replimune Group Inc | $7.8M | 1,015,400 | — | 0.3% | — | |
| — | — | AxoGen Inc AxoGen Inc · COM CUSIP 05463X106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.0M | 210,665 | — | 0.3% | — | |
| — | DFTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Definium Therapeutics Inc Definium Therapeutics Inc · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.5M | 344,166 | — | 0.2% | — | |
| — | — | Cytokinetics Inc Cytokinetics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.0M | 91,791 | — | 0.2% | — | |
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Disc Medicine Inc Disc Medicine Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.0M | 78,320 | — | 0.2% | — | |
| — | MANEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Veradermics Inc Veradermics Inc · COMMON STOCK CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.6M | 73,315 | — | 0.2% | — | |
| — | — | Harmony Biosciences Hldgs Inc Harmony Biosciences Hldgs Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.3M | 152,695 | — | 0.2% | — | |
| — | PCVXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Vaxcyte Inc Vaxcyte Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.9M | 50,600 | — | 0.1% | — | |
| — | MIRMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.5M | 27,591 | — | 0.1% | — | |
| — | — | Nextcure Inc Nextcure Inc · COM CUSIP 65343E207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.4M | 222,654 | — | 0.1% | — | |
| — | — | Savara Inc Savara Inc · COM CUSIP 805111101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.0M | 364,763 | — | 0.1% | — | |
| — | — | Establishment Labs Hldgs Inc Establishment Labs Hldgs Inc · COM CUSIP G31249108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.9M | 33,930 | — | 0.1% | — | |
| — | ACADverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Acadia Pharmaceuticals Inc Acadia Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.7M | 78,551 | — | 0.1% | — | |
| — | — | Tenax Therapeutics Inc Tenax Therapeutics Inc · COM CUSIP 88032L605 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.7M | 104,400 | — | 0.1% | — | |
| — | — | Jade Biosciences Inc Jade Biosciences Inc · COM CUSIP 008064206 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.5M | 107,391 | — | 0.1% | — | |
| — | WVEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Wave Life Sciences Ltd Wave Life Sciences Ltd · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.4M | 189,253 | — | 0.1% | — | |
| — | — | Septerna Inc Septerna Inc · COM CUSIP 81734D104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.1M | 47,506 | — | 0.0% | — | |
| — | — | Onkure Therapeutics Inc Onkure Therapeutics Inc · COM CL A CUSIP 68277Q105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $587K | 141,700 | — | 0.0% | — | |
| — | — | Bolt Biotherapeutics Inc Bolt Biotherapeutics Inc · COM CUSIP 097702203 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $556K | 137,721 | — | 0.0% | — | |
| — | — | Soleno Therapeutics Inc Soleno Therapeutics Inc · COM CUSIP 834203309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $492K | 14,689 | — | 0.0% | — | |
| — | — | ImageneBio Inc ImageneBio Inc · COM CUSIP 45175G207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $159K | 31,884 | — | 0.0% | — | |
| — | — | Zymeworks Inc Zymeworks Inc · COM CUSIP 98985Y108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $40.3K | 1,610 | — | 0.0% | — |
1–68 of 68 issuers · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).